Purpose: No published head-to-head randomized trials have compared the safety and
efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration …

Darolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown
to increase metastasis-free survival and overall survival among men with non-metastatic …

Context Second‐generation androgen receptor inhibitors (ARIs) extend metastasis‐free
survival, prolong overall survival, and delay symptoms when added to androgen deprivation …

Docetaxel could inhibit the proliferation of tumor cells by targeting microtubules. The
extension of cellular microtubules plays an important role in the invasion and metastasis of …

Introduction Three novel androgen receptor inhibitors are approved in the USA for the
treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide …

Background Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are
usually asymptomatic and seek treatments that improve survival but have a low risk of …

Methods A paper-based discrete choice experiment (DCE) survey was administered to 80
nmCRPC-treating physicians. DCE responses were analyzed to produce the preference …

PURPOSE Sixteen percent (16%) of patients with castration-resistant prostate cancer
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …

Background/Objectives: Patients with non-metastatic castration-resistant prostate cancer
(nmCRPC) and high-risk features frequently have progression to life-threatening metastasis …

Oral darolutamide (Nubeqa™) is a novel second-generation, nonsteroidal, selective
androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration …